Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2024 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Among authors: addo boateng f. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).
Tumusiime VB, Ruzagira E, Norcross C, Eshun-Wilsonova I, Kitonsa J, Bahemuka UM, Grint D, Kimbugwe G, Kakande A, Lawrence DS, Mwendia F, Van Solingen R, Van Eygen V, Addo Boateng F, Cresswell F; IMPALA study team. Tumusiime VB, et al. Among authors: addo boateng f. Wellcome Open Res. 2025 Mar 28;10:166. doi: 10.12688/wellcomeopenres.23363.1. eCollection 2025. Wellcome Open Res. 2025. PMID: 41040645 Free PMC article.
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Yawe I, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Okwero M, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Among authors: addo boateng f. Nat Med. 2026 Jan;32(1):168-177. doi: 10.1038/s41591-025-04041-7. Epub 2025 Nov 4. Nat Med. 2026. PMID: 41188524 Free PMC article. Clinical Trial.